TOP TEN perturbations for 38507_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38507_at
Selected probe(set): 207498_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38507_at (207498_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

hepatoblastoma study 1 (embryonal) / normal liver tissue

Relative Expression (log2-ratio):-4.177782
Number of Samples:7 / 5
Experimental hepatoblastoma study 1 (embryonal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (NOS) / normal liver tissue

Relative Expression (log2-ratio):-4.176399
Number of Samples:5 / 5
Experimental hepatoblastoma study 1 (NOS)
Liver tumor tissue samples from children with hepatoblastoma (NOS). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (mixed epithelial and mesenchymal) / normal liver tissue

Relative Expression (log2-ratio):-4.0841484
Number of Samples:4 / 5
Experimental hepatoblastoma study 1 (mixed epithelial and mesenchymal)
Liver tumor tissue samples from children with hepatoblastoma (mesenchymal type (MEM-HB); mixed epithelial and mesenchymal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (epithelial mixed) / normal liver tissue

Relative Expression (log2-ratio):-3.8483934
Number of Samples:12 / 5
Experimental hepatoblastoma study 1 (epithelial mixed)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

HCC study 23 (portal vein infiltration) / adjacent liver tissue

Relative Expression (log2-ratio):-3.3405352
Number of Samples:3 / 10
Experimental HCC study 23 (portal vein infiltration)
Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.
Control adjacent liver tissue
Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.

hepatoblastoma study 1 (fetal) / normal liver tissue

Relative Expression (log2-ratio):-3.0416317
Number of Samples:4 / 5
Experimental hepatoblastoma study 1 (fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (mixed embryonal and fetal) / normal liver tissue

Relative Expression (log2-ratio):-3.0387354
Number of Samples:13 / 5
Experimental hepatoblastoma study 1 (mixed embryonal and fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); mixed embryonal and fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

HCC study 18 (very advanced) / dysplastic liver nodule study 1

Relative Expression (log2-ratio):-3.0239277
Number of Samples:3 / 17
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control dysplastic liver nodule study 1
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

hepatoblastoma study 1 (crowded fetal) / normal liver tissue

Relative Expression (log2-ratio):-2.5706425
Number of Samples:3 / 5
Experimental hepatoblastoma study 1 (crowded fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); crowded fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

HCC study 23 (portal vein infiltration) / HCC study 23 (no portal vein infiltration)

Relative Expression (log2-ratio):-2.5379562
Number of Samples:3 / 7
Experimental HCC study 23 (portal vein infiltration)
Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.
Control HCC study 23 (no portal vein infiltration)
Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) without portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.